Report cover image

Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2023-2029

Publisher QYResearch Group
Published Aug 01, 2023
Length 156 Pages
SKU # QYR18095234

Description

Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2023-2029



Due to the COVID-19 pandemic, the global Radioimmunotherapy market size was US$ 1042.83 million in 2022 and is forecast to a readjusted size of US$ 4479 million by 2029 with a CAGR of 17.43% during the forecast period 2023-2029.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, and etc. In 2022, the global top five players hold a share approximately 99.25% in terms of revenue.

The United States Radioimmunotherapy market size was US$ 504.62 million in 2022, while China size was US$ 23.72 million. The proportion of the United States was 48.39% in 2022, while China percentage was 2.27%, and it is predicted that China share will reach 1.44% in 2029, trailing a CAGR of 20.26 % through the analysis period. As for the Europe Radioimmunotherapy landscape, Germany is projected to reach US$ 327 million by 2029.

The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Radioimmunotherapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Radioimmunotherapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Radioimmunotherapy market. Readers of the report can become informed about current and future trends of the global Radioimmunotherapy market and how they will impact market growth during the forecast period.

By Company

On Market

Bayer

Novartis

Lantheus

Aurobindo Pharma

Mundipharma

China Isotope & Radiation

Curium Pharmaceuticals

On Pipeline

Gilead Sciences

Clarity Pharmaceuticals

Curasight

Nordic Nanovector

Philogen

RadioMedix

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

Segment by Type

Beta-emitting

Targeted Alpha Therapy

Segment by Application

Non Hodgkin Lymphoma (NHL)

Solid Tumor

By Region

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Middle East & Africa

Middle East

Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.

Chapter 2: Revenue of Radioimmunotherapy in global and regional level.

Chapter 3: Detailed analysis of Radioimmunotherapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.

Chapter 9: Latin America by Type, by Application and by country, revenue for each segment.

Chapter 10: Middle East and Africa, by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin, and Business Strategy, etc.

Chapter 12: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 13: Research Findings and Conclusion

Table of Contents

156 Pages
1 Report Overview
1.1 Study Scope
1.2 Market Analysis By Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate By Type: 2018 Vs 2022 Vs 2029
1.2.2 Targeted Alpha Therapy
1.2.3 Beta-emitting
1.3 Market By Application
1.3.1 Global Radioimmunotherapy Market Growth By Application: 2018 Vs 2022 Vs 2029
1.3.2 Non Hodgkin Lymphoma (Nhl)
1.3.3 Solid Tumor
1.4 Assumptions And Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Radioimmunotherapy Market Size 2018-2029
2.2 Radioimmunotherapy Market Size Across Key Geographies Worldwide: 2018 Vs 2022 Vs 2029
2.3 Global Radioimmunotherapy Market Size By Region (2018-2023)
2.4 Global Radioimmunotherapy Market Size Forecast By Region (2024-2029)
2.5 Global Top 10 Radioimmunotherapy Countries Ranking By Market Size
3 Radioimmunotherapy Competition By Company
3.1 Global Radioimmunotherapy Revenue By Players
3.1.1 Global Radioimmunotherapy Revenue By Players (2018-2023)
3.1.2 Global Radioimmunotherapy Market Share By Players (2018-2023)
3.2 Global Radioimmunotherapy By Company Type (Tier 1, Tier 2, And Tier 3)
3.3 Company Covered: Ranking By Radioimmunotherapy Revenue
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (Cr5 And Hhi)
3.4.2 Global Top 5 Companies By Radioimmunotherapy Revenue In 2022
3.5 Global Key Players Of Radioimmunotherapy Head Office And Area Served
3.6 Global Key Players Of Radioimmunotherapy, Product And Application
3.7 Global Key Players Of Radioimmunotherapy, Date Of Enter Into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Radioimmunotherapy Breakdown Data By Type
4.1 Global Radioimmunotherapy Historic Market Size By Type (2018-2023)
4.2 Global Radioimmunotherapy Forecasted Market Size By Type (2024-2029)
5 Global Radioimmunotherapy Breakdown Data By Application
5.1 Global Radioimmunotherapy Historic Market Size By Application (2018-2023)
5.2 Global Radioimmunotherapy Forecasted Market Size By Application (2024-2029)
6 North America
6.1 North America Radioimmunotherapy Revenue By Company (2021-2023)
6.2 North America Radioimmunotherapy Revenue By Type (2018-2029)
6.3 North America Radioimmunotherapy Revenue By Application (2018-2029)
6.4 North America Radioimmunotherapy Revenue By Country (2018-2029)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Radioimmunotherapy Revenue By Company (2021-2023)
7.2 Europe Radioimmunotherapy Revenue By Type (2018-2029)
7.3 Europe Radioimmunotherapy Revenue By Application (2018-2029)
7.4 Europe Radioimmunotherapy Revenue By Country (2018-2029)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Radioimmunotherapy Revenue By Company (2021-2023)
8.2 Asia Pacific Radioimmunotherapy Revenue By Type (2018-2029)
8.3 Asia Pacific Radioimmunotherapy Revenue By Application (2018-2029)
8.4 Asia Pacific Radioimmunotherapy Revenue By Region (2018-2029)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Southeast Asia
9 Latin America
9.1 Latin America Radioimmunotherapy Revenue By Company (2021-2023)
9.2 Latin America Radioimmunotherapy Revenue By Type (2018-2029)
9.3 Latin America Radioimmunotherapy Revenue By Application (2018-2029)
9.4 Latin America Radioimmunotherapy Revenue By Country (2018-2029)
9.4.1 Mexico
9.4.2 Brazil
10 Middle East And Africa
10.1 Middle East And Africa Radioimmunotherapy Revenue By Company (2021-2023)
10.2 Middle East And Africa Radioimmunotherapy Revenue By Type (2018-2029)
10.3 Middle East And Africa Radioimmunotherapy Revenue By Application (2018-2029)
10.4 Middle East And Africa Radioimmunotherapy Revenue By Country (2018-2029)
10.4.1 Middle East
10.4.2 Africa
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Radioimmunotherapy Products And Services
11.1.4 Bayer Revenue In Radioimmunotherapy Business (2018-2023)
11.1.5 Bayer Radioimmunotherapy Swot Analysis
11.1.6 Bayer Business Strategy
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Radioimmunotherapy Products And Services
11.2.4 Novartis Revenue In Radioimmunotherapy Business (2018-2023)
11.2.5 Novartis Radioimmunotherapy Swot Analysis
11.2.6 Novartis Business Strategy
11.3 Lantheus
11.3.1 Lantheus Company Details
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Radioimmunotherapy Products And Services
11.3.4 Lantheus Revenue In Radioimmunotherapy Business (2018-2023)
11.3.5 Lantheus Radioimmunotherapy Swot Analysis
11.3.6 Lantheus Business Strategy
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Radioimmunotherapy Products And Services
11.4.4 Aurobindo Pharma Revenue In Radioimmunotherapy Business (2018-2023)
11.4.5 Aurobindo Pharma Radioimmunotherapy Swot Analysis
11.4.6 Aurobindo Pharma Business Strategy
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Radioimmunotherapy Products And Services
11.5.4 Mundipharma Revenue In Radioimmunotherapy Business (2018-2023)
11.5.5 Mundipharma Business Strategy
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Details
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Radioimmunotherapy Products And Services
11.6.4 China Isotope & Radiation Revenue In Radioimmunotherapy Business (2018-2023)
11.6.5 China Isotope & Radiation Radioimmunotherapy Swot Analysis
11.6.6 China Isotope & Radiation Business Strategy
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Details
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products And Services
11.7.4 Curium Pharmaceuticals Revenue In Radioimmunotherapy Business (2018-2023)
11.7.5 Curium Pharmaceuticals Radioimmunotherapy Swot Analysis
11.7.6 Curium Pharmaceuticals Business Strategy
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Radioimmunotherapy Products And Services
11.8.4 Gilead Sciences Business Strategy
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Details
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products And Services
11.9.4 Clarity Pharmaceuticals Radioimmunotherapy Swot Analysis
11.9.5 Clarity Pharmaceuticals Business Strategy
11.10 Curasight
11.10.1 Curasight Company Details
11.10.2 Curasight Business Overview
11.10.3 Curasight Radioimmunotherapy Products And Services
11.10.4 Curasight Radioimmunotherapy Swot Analysis
11.10.5 Curasight Business Strategy
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Details
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Radioimmunotherapy Products And Services
11.11.4 Nordic Nanovector Radioimmunotherapy Swot Analysis
11.11.5 Nordic Nanovector Business Strategy
11.12 Philogen
11.12.1 Philogen Company Details
11.12.2 Philogen Business Overview
11.12.3 Philogen Radioimmunotherapy Products And Services
11.12.4 Philogen Radioimmunotherapy Swot Analysis
11.12.5 Philogen Business Strategy
11.13 Radiomedix
11.13.1 Radiomedix Company Details
11.13.2 Radiomedix Business Overview
11.13.3 Radiomedix Radioimmunotherapy Products And Services
11.13.4 Radiomedix Business Strategy
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Details
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products And Services
11.14.4 Telix Pharmaceuticals Radioimmunotherapy Swot Analysis
11.14.5 Telix Pharmaceuticals Business Strategy
11.15 Orano Med
11.15.1 Orano Med Company Details
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Radioimmunotherapy Products And Services
11.15.4 Orano Med Radioimmunotherapy Swot Analysis
11.15.5 Orano Med Business Strategy
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Details
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products And Services
11.16.4 Actinium Pharmaceuticals Radioimmunotherapy Swot Analysis
11.16.5 Actinium Pharmaceuticals Business Strategy
11.17 Y-mabs Therapeutics
11.17.1 Y-mabs Therapeutics Company Details
11.17.2 Y-mabs Therapeutics Business Overview
11.17.3 Y-mabs Therapeutics Radioimmunotherapy Products And Services
11.17.4 Y-mabs Therapeutics Business Strategy
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Details
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products And Services
11.18.4 Fusion Pharmaceuticals Business Strategy
12 Radioimmunotherapy Market Dynamics
12.1 Radioimmunotherapy Industry Trends
12.2 Radioimmunotherapy Market Drivers
12.3 Radioimmunotherapy Market Challenges
12.4 Radioimmunotherapy Market Restraints
13 Research Findings And Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List Of Tables
Table 1. Global Radioimmunotherapy Market Size Growth Rate (Cagr) By Type (Us$ Million): 2018 Vs 2022 Vs 2029
Table 2. Key Players Of Ibritumomab
Table 3. Key Players Of Apamistamab
Table 4. Key Players Of Lilotomab
Table 5. Key Players Of Omburtamab
Table 6. Global Radioimmunotherapy Market Size Growth Rate (Cagr) By Application (Us$ Million): 2018 Vs 2022 Vs 2029
Table 7. Global Radioimmunotherapy Market Size (Us$ Million) Growth Rate (Cagr) By Region: 2018 Vs 2022 Vs 2029
Table 8. Global Radioimmunotherapy Revenue By Region (2018-2023) & (Us$ Million)
Table 9. Global Radioimmunotherapy Revenue Forecast By Region (2024-2029) & (Us$ Million)
Table 10. Global Radioimmunotherapy Market Size Of Top 10 Countries, 2018 Vs 2022 Vs 2029, (Us$ Million)
Table 11. Global Radioimmunotherapy Revenue By Players (2018-2023) & (Us$ Million)
Table 12. Global Radioimmunotherapy Market Share By Players (2018-2023)
Table 13. Global Top Radioimmunotherapy Players By Company Type (Tier 1, Tier 2, And Tier 3) & (Based On The Revenue In Radioimmunotherapy As Of 2022)
Table 14. Ranking Of Global Top Radioimmunotherapy Companies By Revenue (Us$ Million) In 2022
Table 15. Global 5 Largest Players Market Share By Radioimmunotherapy Revenue (Cr5 And Hhi) & (2018-2023)
Table 16. Global Key Players Of Radioimmunotherapy, Headquarters And Area Served
Table 17. Global Key Players Of Radioimmunotherapy, Product And Application
Table 18. Global Key Players Of Radioimmunotherapy, Date Of Enter Into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Radioimmunotherapy Market Size By Type (2018-2023) & (Us$ Million)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us